Jason D. Brubaker

Statistics

Publications

Citations

1.3K

H-Index

Active since

2003

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Blueprint Medicines (United States)

Harvard University

University of Connecticut

Jason D. Brubaker is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicinal chemistry, drug discovery, and pharmacology.

Publications per year

2003–2024

Publications

Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven Cancers

Vivek Subbiah, Justin F. Gainor, Rami Rahal et al. · Cancer Discovery · 2018 · 393 citations

Medicine, Oncology, Pharmacology +17

A Convergent Enantioselective Route to Structurally Diverse 6-Deoxytetracycline Antibiotics

Mark G. Charest, C. Lerner, Jason D. Brubaker et al. · Science · 2005 · 297 citations

Pharmacy, Medicinal Chemistry, Drug Design +8

Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer

Meredith S. Eno, Jason D. Brubaker, John E. Campbell et al. · Journal of Medicinal Chemistry · 2022 · 160 citations · Full text

Medicine, Oncology, Pharmacology +14

A Robust Platform for the Synthesis of New Tetracycline Antibiotics

Cuixiang Sun, Qiu Wang, Jason D. Brubaker et al. · Journal of the American Chemical Society · 2008 · 130 citations · Full text

Natural Sciences, Chemistry, Medicinal Chemistry +14

A Practical, Enantioselective Synthetic Route to a Key Precursor to the Tetracycline Antibiotics

Jason D. Brubaker, Andrew G. Myers · Organic Letters · 2007 · 77 citations · Full text

Natural Sciences, Chemistry, Medicinal Chemistry +8

1–5 of 15